The agency recommended labs stock up on these types of testing kits as it looks to withdraw its emergency use authorization request to the FDA after Dec. 31 for one of the earliest real-time diagnostic tests for COVID-19. The CDC 2019-Novel Coronavirus Real-time [Polymerase Chain Reaction] Diagnostic Panel was introduced in February 2020 and detects only SARS-CoV-2, the virus that causes a COVID-19 infection.
“CDC is providing this advance notice for clinical laboratories to have adequate time to select and implement one of the many FDA-authorized alternatives,” the notice said, urging labs to adopt “a multiplexed method that can facilitate detection and differentiation of SARS-CoV-2 and influenza viruses.”
“Such assays can facilitate continued testing for both influenza and SARS-CoV-2 and can save both time and resources as we head into influenza season.”
To view the FDA’s list of authorized COVID-19 diagnostic tests, click here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
